Contrasting International Stem Cell (OTCMKTS:ISCO) and Salarius Pharmaceuticals (NASDAQ:SLRX)

Earnings & Valuation

This table compares International Stem Cell and Salarius Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Stem Cell	$7.79 million	N/A	-$130,000.00	($0.08)	-1.17
Salarius Pharmaceuticals	$1.84 million	1.19	-$12.54 million	($8.17)	-0.19

International Stem Cell has higher revenue and earnings than Salarius Pharmaceuticals. International Stem Cell is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

International Stem Cell has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares International Stem Cell and Salarius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
International Stem Cell	-6.80%	N/A	-10.77%
Salarius Pharmaceuticals	N/A	-140.28%	-105.76%

Institutional & Insider Ownership

11.9% of Salarius Pharmaceuticals shares are held by institutional investors. 81.5% of International Stem Cell shares are held by company insiders. Comparatively, 1.4% of Salarius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

International Stem Cell beats Salarius Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About International Stem Cell

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.